|
Search for our Investigators on Pub
Med
|
WILLIAM J. M. HRUSHESKY, M.D.
Lab
LAB PERSONNEL
Bill Hrushesky, M.D. Adjunct Professor, USC
Director of Research, Dorn VA Med Center
PATENTS (U.S.) and COPYRIGHTS
Sine-O-Graph: Diagnostic Medical Device to Measure
Myocardial Compliance Noninvasively. US Patent #4,519,395
(awarded 05/28/85), Canadian Patent #1,196,012 (awarded
10/19/85), European Patent Application #83,307,347.1
(pending), Japanese Patent Application #232902/83 (pending)
Sinus Arrhythmia Monitor: US Patent #4,930,518 (awarded
06/05/90)
Method and Agents for Raising Animal Tolerance to Oxidant
Stress-Inducing Antibiotics: Chemical Method of Modifying
Drug Toxicity by Modulating Intracellular Redox Status. US
Patent #4,548,927 (awarded 10/22/85)
Needle Support System: Medical Device Stabilizing Access to
Subcutaneous Vascular Access Systems and Implant Drug Pumps.
US Patent #4,675,006 (awarded 06/23/87)
Infuse-a-Fill Manual: Guide to Safe Continuous Chemotherapy
Infusion. Copyright (1984)
One-Piece Catheter Access Port with Guide Wire: Letter of
Disclosure (12/08/86), U of MN Patent Office
Rodent Inject-Aid: Laboratory Device Allowing Fast and
Simple Murine Access Systems. US Patent #4,709,660 (awarded
12/01/87)
Method and Device for Closed-Loop Local Immunomodulation:
Patent Pending
Biodegradable Pulsatile Osmotic Delivery System: Patent
Pending
Method for Noninvasive Measurement of Gut Toxicity:
Disclosure Pending, Co-Inventor
 |
 |
PUBLICATIONS
Books:
Temporal Control of Drug Delivery. Hrushesky WJM, Langer R,
Theeuwes F (Editors). Annal NY Academy of Science, Volume
618, 1991.
Circadian Cancer Therapy. Hrushesky WJM (Editor). CRC Press,
May 1994.
Monographs:
Cancer Chronotherapy. Hrushesky WJM (Editor). Journal of
Infusional Chemotherapy 2 (2), April,1992.
Scientific Basis for Circadian Cancer Therapy. Hrushesky WJM
(Editor). Journal of Infusional Chemotherapy 3 (3), July
1993.
Larry Scheving Symposium. Hrushesky WJM (Editor). Journal of
Infusional Chemotherapy 5 (1), Winter 1995.
Papers:
Hrushesky WJ, Sothern RB, Rietveld WJ, Du Quiton J, Boon ME.
Season, sun, sex, and cervical cancer. Cancer Epidemiol
Biomarkers Prev. 2005 Aug;14(8):1940-7.
Wood PA, Bove K, You S, Chambers A, Hrushesky WJ. Cancer
growth and spread are saltatory and phase-locked to the
reproductive cycle through mediators of angiogenesis. Mol
Cancer Ther. 2005 Jul;4(7):1065-75.
Demicheli R, Miceli R, Moliterni A, Zambetti M, Hrushesky WJ,
Retsky MW, Valagussa P, Bonadonna G. Breast cancer
recurrence dynamics following adjuvant CMF is consistent
with tumor dormancy and mastectomy-driven acceleration of
the metastatic process. Ann Oncol. 2005 Sep;16(9):1449-57.
Wood PA, Hrushesky WJ. Sex cycle modulates cancer growth.
Breast Cancer Res Treat. 2005 May;91(1):95-102.
You S, Wood PA, Xiong Y, Kobayashi M, Du-Quiton J, Hrushesky
WJ. Daily coordination of cancer growth and circadian clock
gene expression. Breast Cancer Res Treat. 2005
May;91(1):47-60.
Baum M, Demicheli R, Hrushesky W, Retsky M. Does surgery
unfavourably perturb the "natural history" of early breast
cancer by accelerating the appearance of distant metastases?
Eur J Cancer. 2005 Mar;41(4):508-15.
Retsky M, Demicheli R, Hrushesky W, Speer J, Swartzendruber
D, Wardwell R. Recent translational research: computational
studies of breast cancer. Breast Cancer Res.
2005;7(1):37-40.
Dominitz JA, Boyko EJ, Koepsell TD, Heagerty PJ, Maynard C,
Sporleder JL, Stenhouse A, Kling MA, Hrushesky W, Zeilman C,
Sontag S, Shah N, Ona F, Anand B, Subik M, Imperiale TF,
Nakhle S, Ho SB, Bini EJ, Lockhart B, Ahmad J, Sasaki A, van
der Linden B, Toro D, Martinez-Souss J, Huilgol V, Eisen S,
Young KA. Elevated prevalence of hepatitis C infection in
users of United States veterans medical centers. Hepatology.
2005 Jan;41(1):88-96.
Demicheli R, Bonadonna G, Hrushesky WJ, Retsky MW, Valagussa
P. Menopausal status dependence of the timing of breast
cancer recurrence after surgical removal of the primary
tumour. Breast Cancer Res. 2004;6(6):R689-96.
Hrushesky W, Wood P, Levi F, von Roemeling R, Bjarnason G,
Focan C, Meier K, Cornelissen G, Halberg F. A recent
illustration of some essentials of circadian chronotherapy
study design. J Clin Oncol. 2004 Jul 15;22(14):2971-2;
author reply 2972.
Retsky M, Bonadonna G, Demicheli R, Folkman J, Hrushesky W,
Valagussa P. Hypothesis: Induced angiogenesis after surgery
in premenopausal node-positive breast cancer patients is a
major underlying reason why adjuvant chemotherapy works
particularly well for those patients. Breast Cancer Res.
2004;6(4):R372-4.
Hrushesky WJ, Blask DE. Re: Melatonin and breast cancer: a
prospective study. J Natl Cancer Inst. 2004 Jun
2;96(11):888-9.
You S, Li W, Kobayashi M, Xiong Y, Hrushesky W, Wood P.
Creation of a stable mammary tumor cell line that maintains
fertility-cycle tumor biology of the parent tumor. In Vitro
Cell Dev Biol Anim. 2004 Jul-Aug;40(7):187-95.
Lis CG, Grutsch JF, Wood P, You M, Rich I, Hrushesky WJ.
Circadian timing in cancer treatment: the biological
foundation for an integrative approach. Integr Cancer Ther.
2003 Jun;2(2):105-11.
Demicheli R, Bonadonna G, Hrushesky WJ, Retsky MW, Valagussa
P. Menopausal status dependence of early mortality reduction
due to diagnosis of smaller breast cancers (T1 v T2-T3):
relevance to screening. J Clin Oncol. 2004 Jan
1;22(1):102-7.
Takeda Y, Yanagie H, Yoshizaki I, Eriguchi M. Does the
timing of surgery for breast cancer in relation to the
menstrual cycle or geomagnetic activity affect prognoses of
premenopausal patients? Biomed Pharmacother. 2003 Oct;57
Suppl 1:96s-103s.
Retsky M, Demicheli R, Hrushesky W. Breast cancer screening:
controversies and future directions. Curr Opin Obstet
Gynecol. 2003 Feb;15(1):1-8.
Bove K, Lincoln DW, Wood PA, Hrushesky WJ. Fertility cycle
influence on surgical breast cancer cure. Breast Cancer Res
Treat. 2002 Sep;75(1):65-72.
Hrushesky WJ. Androgen suppression and irradiation for
locally advanced prostate cancer. Lancet. 2002 Dec
14;360(9349):1987; author reply 1987-8.
Hrushesky WJ. Re: Mastectomy and oophorectomy by menstrual
cycle phase in women with operable breast cancer. J Natl
Cancer Inst. 2002 Nov 20;94(22):1720-1.
Kobayashi M, Wood PA, Hrushesky WJ. Circadian chemotherapy
for gynecological and genitourinary cancers. Chronobiol Int.
2002 Jan;19(1):237-51.
Takeda Y, Nonaka Y, Yanagie H, Yoshizaki I, Eriguchi M.
Correlation between timing of surgery in relation to the
menstrual cycle and prognosis of premenopausal breast cancer
patients. Biomed Pharmacother. 2001;55 Suppl 1:133s-137s.
Retsky M, Demicheli R, Hrushesky W. Breast cancer screening
for women aged 40-49 years: screening may not be the benign
process usually thought. J Natl Cancer Inst. 2001 Oct
17;93(20):1572.
Hrushesky WJ. Tumor chronobiology. J Control Release. 2001
Jul 6;74(1-3):27-30.
Bjarnason GA, Jordan RC, Wood PA, Li Q, Lincoln DW, Sothern
RB, Hrushesky WJ, Ben-David Y. Circadian expression of clock
genes in human oral mucosa and skin: association with
specific cell-cycle phases. Am J Pathol. 2001
May;158(5):1793-801.
Retsky M, Demicheli R, Hrushesky W. Premenopausal status
accelerates relapse in node positive breast cancer:
hypothesis links angiogenesis, screening controversy. Breast
Cancer Res Treat. 2001 Feb;65(3):217-24.
Retsky M, Demicheli R, Hrushesky W. Wounding from biopsy and
breast-cancer progression. Lancet. 2001 Mar
31;357(9261):1048.
Mizumura Y, Matsumura Y, Hamaguchi T, Nishiyama N, Kataoka
K, Kawaguchi T, Hrushesky WJ, Moriyasu F, Kakizoe T.
Cisplatin-incorporated polymeric micelles eliminate
nephrotoxicity, while maintaining antitumor activity. Jpn J
Cancer Res. 2001 Mar;92(3):328-36.
Hrushesky WJ. The temporal organization of life: the impact
of multi-frequency non-linear biologic time structure upon
the host-cancer balance. Jpn J Clin Oncol. 2000
Dec;30(12):529-33.
Lincoln DW 2nd, Hrushesky WJ, Wood PA. Circadian
organization of thymidylate synthase activity in normal
tissues: a possible basis for 5-fluorouracil
chronotherapeutic advantage. Int J Cancer. 2000 Nov
1;88(3):479-85.
Hrushesky WJ. Rhythmic menstrual cycle modulation of breast
cancer biology. J Surg Oncol. 2000 Jul;74(3):238-41.
Thrall MM, Wood P, King V, Rivera W, Hrushesky W.
Investigation of the comparative toxicity of 5-FU bolus
versus 5-FU continuous infusion circadian chemotherapy with
concurrent radiation therapy in locally advanced rectal
cancer. Int J Radiat Oncol Biol Phys. 2000 Mar
1;46(4):873-81.
Nomura Y, Kataoka A, Tsutsui S, Murakami S, Takenaka Y. Lack
of correlation between timing of surgery in relation to the
menstrual cycle and prognosis of premenopausal patients with
early breast cancer. Eur J Cancer. 1999 Sep;35(9):1326-30.
Hrushesky WJ, Vyzula R, Wood PA. Fertility maintenance and
5-fluorouracil timing within the mammalian fertility cycle.
Reprod Toxicol. 1999 Sep-Oct;13(5):413-20.
Hrushesky WJ, Lester B, Lannin D. Circadian coordination of
cancer growth and metastatic spread. Int J Cancer. 1999 Oct
29;83(3):365-73.
Hrushesky WJ, Lannin D, Haus E. Evidence for an ontogenetic
basis for circadian coordination of cancer cell
proliferation. J Natl Cancer Inst. 1998 Oct 7;90(19):1480-4.
Wood PA, Hrushesky WJ, Klevecz R. Distinct circadian time
structures characterize myeloid and erythroid progenitor and
multipotential cell clonogenicity as well as marrow
precursor proliferation dynamics. Exp Hematol. 1998
Jun;26(6):523-33.
Hagen AA, Hrushesky WJ. Menstrual timing of breast cancer
surgery. Am J Surg. 1998 Mar;175(3):245-61.
Tzannis S, Hrushesky W, Wood P, Przybycien T. Adsorption of
a formulated protein on a drug delivery device surface. J
Colloid Interface Sci 1997. 189: 216-228
Hrushesky W. Breast cancer, surgery, and the menstrual
cycle. In: Salmon S, ed. Adjuvant Therapy of Cancer VIII.
Philadelphia: Lippincott-Raven, 1997: 133-144.
Hrushesky W, Wood P. Circadian time structure of septic
shock: Timing is everything [letter to editor]. J Infect Dis
1997; 175 (May):1283-84.
Wood P, Hrushesky W. Cisplatin-associated anemia: An
erythropoietin deficiency syndrome [abstract]. Oncology
Digest, 1997;2:(Investigation).
Wood P, Hrushesky W. Cisplatin-associated anemia: An
erythropoietin deficiency syndrome [abstract]. In: Spivak JL,
ed. Yearbook of Hematology. St. Louis: Mosby, 1997:3-4.
Hrushesky W. Cosmos, geos, bios, homos. In: Razis, DV (ed.).
Multifrequency chao-periodic competitors for global impact.
The Human Predicament: An International Dialogue on the
Meaning of Human Behavior. Amherst, New York: Prometheus
Books, 1996:79-85.
Hrushesky W. Chao-periodic patterns in the achievement of
understanding. In: Razis, DV (ed.). The Human Predicament:
An International Dialogue on the Meaning of Human Behavior.
Amherst, New York: Prometheus Books, 1996:171-181.
Hrushesky W. Breast cancer, timing of surgery, and the
menstrual cycle: Call for prospective trial. J Women's
Health 1996; 5:555-565.
Tzannis S, Hrushesky W, Wood P, Przybycien T. Irreversible
inactivation of interleukin-2 in a pump-based delivery
environment. Proc Natl Acad Sci USA 1996; 93:5460-5465.
Hrushesky W, Marsh RdW, Wood P. Circadian pharmacodynamics.
In: Schilsky R, Milano G, Ratain M, eds. Principles of
Antineoplastic Drug Development and Pharmacology. New York:
Marcel Dekker, Inc., 1996:681-720.
Wood P, Hrushesky W. Circadian timing of cancer
chemotherapy. In: Perry M, ed. The Chemotherapy Source Book.
Vol. 2nd edition: Williams and Wilkins, 1996:177-202.
Hrushesky W. Cancer chronotherapy: is there a right time in
the day to treat? J Infus Chemo 1995; 5:38-43.
Hrushesky W. Preface: Larry Scheving and cancer
chronotherapy. J Infus Chemo 1995; 5:1-3.
Wong M, Bjarnason G, Hrushesky W, Webster P, Morava-Protzner
I, Towers M. Steroid-responsive interstitial lung disease in
patients receiving 2'-deoxy-5-fluorouridine-infusion
chemotherapy. Cancer 1995; 75:2558-2564.
Hrushesky W. Circadian Anticancer Treatment (Erna Halberg
memorial). In Vivo 1995:315-321.
Hrushesky W. Menstrual cycle timing of breast cancer
resection: prospective study is overdue. J Natl Cancer Inst
1995; 87:143-144.
Hrushesky W. Square pegs in round holes [Letter to the
editor]. Int J Cancer 1995; 62:651-652.
Wood P, Hrushesky W. Erythropoietin usage in patients with
cancer. Cancer J 1995; 1, November/December:243-246.
Wood P, Hrushesky W. Biological perspectives on circadian
cancer therapy. J of Inf Chemo 1995; 5:182-190.
Wood P, Hrushesky W. Cisplatin-associated anemia: an
erythropoietin deficiency syndrome. J Clin Invest 1995;
95:1650-1659.
Hrushesky W. Introduction: cancer and time. In: Hrushesky W,
ed. Circadian Cancer Therapy: CRC Press, 1994:3-9.
Hrushesky W. Mammography and the menstrual cycle [Letter to
editor]. International J Cancer 1994:151.
Hrushesky W, Cope F. Fluoropyrimidine cancer chronotherapy.
In: Banzet P, Holland J, Khayat D, Weil M, eds. Cancer
Treatment: An Update. Paris, New York and Berlin: Springer-Verlag,
1994:29-39.
Hrushesky W. For autonomy and quality, consider a national
health service. Oncology Times 1994; 16:40-41.
Hrushesky W. Timing is everything. The Sciences 1994;
July/August:32-37.
Hrushesky W. Epilogue: implications of rhythmic biodynamics
for science, cancer drug and cancer therapy development. In:
Hrushesky W, ed. Circadian Cancer Therapy: CRC Press,
1994:279-281.
Hrushesky W, Langevin T, Kim Y, Wood P. Circadian dynamics
of tumor necrosis factor _ (Cachectin) lethality. J Exp Med
1994; 180:1059-1065.
Hrushesky W, Deykin D, Higgins G. The VA unique clinical
cancer research effort. Cancer 1994; 74:2701-2709.
Bjarnason G, Hrushesky W. Preclinical trials of cancer
chronotherapy. In: Hrushesky W, ed. Circadian Cancer
Therapy: CRC Press, 1994:211-239.
Bjarnason G, Hrushesky W. Cancer chronotherapy. In:
Hrushesky W, ed. Circadian Cancer Therapy: CRC Press,
1994:240-263.
Tzannis S, Hrushesky W, Wood P, Przybycien T.
Protein-surface interactions lead to incomplete delivery of
interleukin-2 with an infusion pump/catheter system,
International Symposia on Controlled Release of Bioactive
Materials, 1994. Vol. 21.
Wood P, Hrushesky W. Chronopharmacodynamics of hematopoietic
growth factors and antitumor cytokines. In: Hrushesky W, ed.
Circadian Cancer Therapy: CRC Press, 1994:185-207.
Tzannis S, Pryzbycien T, Hrushesky W, Wood P. The impact of
formulated Interleukin-2/delivery device surface
interactions on bioefficacy, Mat Res Soc Symp Proc, 1994.
Vol. 331:227-232.
Hrushesky W. Cancer and time. In: Macey S, ed. The
Encyclopedia of Time. New York: Garland Publishing, Inc.,
1994:80-83.
Hrushesky W, Bjarnason G. Circadian cancer therapy. J Clin
Oncol 1993; 11:1403-1417.
Hrushesky W, Bjarnason G, Vyzula R. Circadian Cancer
Chronotherapy. In: Cvitkovic E, Droz J, Armand J, Khoury S,
eds. Handbook of Chemotherapy in Clinical Oncology:
Scientific Communication International, Ltd., 1993:109-119.
Hrushesky W. Circadian pharmacodynamics of anticancer
therapies. Clinical Chemistry 1993; 39:2413-2418.
Hrushesky W. Cancer: when in the day to treat. J Infus Chemo
1993; 3:82-88.
Hrushesky W. Circadian cancer pharmacodynamics. Ann First
Super Sanita 1993; 29:705-710.
Hrushesky W. Chronobiology: a modern science with ancient
origins. English Audio Reviews 1993; 4:93-97.
Hrushesky W. Diminishing breast cancer chemotherapy toxicity
by respecting biological rhythms. Y-ME Hotline 1993;
September/October.
Hrushesky W. Breast cancer and the menstrual cycle
[Editorial]. J Surg Oncol 1993; 53:1-3.
Wood P, Vyzula R, Hrushesky W. Circadian hematopoietic
growth factor chronotherapy. J Infus Chemo 1993; 3:89-101.
Hrushesky W. Theoretical and practical implications of
circadian pharmacodynamics. J Infus Chemo 1992; 2:66-68.
Hrushesky W. Infusional chrono-chemotherapy for cancer. J
Infus Chemo 1992; 2:64.
Hrushesky W, Bjarnason G. The application of chronobiology
to cancer medicine. In: DeVita V, Hellman S, Rosenberg S,
eds. Cancer: Principles and Practice of Oncology: J.B.
Lippincott Co., 1992:2666-2686.
Gruber S, Erdmann G, Burke B, Moss A, Bowers L, Hrushesky W,
Cipolle R, Canafax D, Matas A. Mizoribine pharmacokinetics
and pharmacodynamics in a canine renal allograft model of
local immunosuppression. Transplantation 1992; 53:12-19.
Hrushesky W, Vyzula R, Slavik M, Wood P, Sánchez de la Peña
S, Vorlíek J. Chronoterapie maligních Onemocnêní. Klinická
Onkologie 1992:5-45.
Hrushesky W. Chrono-chemotherapy. In: Klein, ed. Renal Cell
Carcinoma: Marcel Dekker, Inc., 1992:325-342.
Wesen C, Roemeling R, Lanning R, Grage T, Olson G, Hrushesky
W. Circadian modification of intra-arterial FUDR infusion
rate reduces its toxicity and permits higher dose intensity.
J Infus Chemo 1992; 2:69-75.
Roemeling R, Krames R, Hrushesky W.
Leucovorin-FUDR-Cisplatin-Interferon (LFCI) salvage
chronotherapy for refractory adenocarcinomas: a phase I/II
study. J Infus Chemo 1992; 2:146-150.
Bjarnason G, Hrushesky W. Circadian cancer chemotherapy:
clinical trials. J Infus Chemo 1992; 2:79-88.
Bluming A, Hrushesky W. Optimal timing of initial breast
cancer surgical [Letter to editor]. Annals of Inter Med
1992; 116:268.
Hrushesky W, Martynowicz M, Markiewicz M, Roemeling R,
Sánchez de la Peña S, Wood P. Chronotherapy of cancer: a
major drug-delivery challenge. Advanced Drug Delivery
Reviews: Chronobiology and chronopharmacology and its
Relevance to the Delivery of Drugs 1992; 9:1-83.
Hrushesky W, Marz W. Chrono-chemotherapy of malignant
tumors: temporal aspects of antineoplastic drug toxicity.
In: Haus E, Touitou I, eds. Biologic Rhythms in Clinical and
Laboratory Medicine. New York: Springer-Verlag,
1992:611-634.
Traynor K, Newton D, Hrushesky W, Reiter R. A pharmacist's
primer on chronotherapeutics. Amer Pharm 1992:1-7.
Lanning R, Hrushesky W. Estimated costs of continuous
infusion chemotherapy. J Infus Chem 1992; 2:89-93.
Bluming A, Hrushesky W. The effect of surgical timing within
the fertility cycle on breast cancer outcome. In: Hrushesky
W, Langer R, Theeuwes F, eds. Temporal Control of Drug
Delivery, Ann NY Acad Sci. Vol. 618, 1991:227-291.
Buchi K, Moore J, Hrushesky W, Sothern R, Rubin N. Circadian
rhythm of cellular proliferation in the human rectal mucosa.
Gastroenterology 1991; 101:410-415.
Gruber S, Canafax D, Cipolle R, Erdmann G, Burke B, Simmons
R, Hrushesky W, Matas A. Intra-arterial infusion of
immunosuppressants, Symposium on Experimental Models in
Transplantation Surgery, Minerva Chiirurrgica, 1991. Vol.
46:75-79.
Hrushesky W. The multifrequency (circadian, fertility cycle
and season) balance between host and cancer. In: Hrushesky
W, Langer R, Theeuwes F, eds. Temporal Control of Drug
Delivery, Ann NY Acad Sci. Vol. 618, 1991:228-256.
Hrushesky W. Preface: temporally optimizable delivery
systems-sine qua non for molecular medicine. In: Hrushesky
W, Langer R, Theeuwes F, eds. Temporal Control of Drug
Delivery, Ann NY Acad Sci. Vol. 618, 1991:xi.
Hrushesky W. Timing of surgery in breast cancer [Letter to
editor]. Lancet 1991; 337:1603-1604.
Hrusehsky W. Chemotherapy, circadian timing and nutrition.
Report of the Ninth Ross Conference on Medical Research:
Ross Laboratories, Columbus, Ohio, 1991:17-24.
Hrushesky W. Quantitative respiratory sinus arrhythmia
analysis: a simple non-invasive, reimbursable measure of
cardiac wellness and dysfunction. Temporal Control of Drug
Delivery, Ann NY Acad Sci 1991; 618:67-101.
Wood P, Sánchez de la Peña S, Hrushesky W. Evidence for
circadian dependency of recombinant human erythropoietin
(rhEPO) response in the mouse. In: Hrushesky W, Langer R,
Theeuwes F, eds. Temporal Control of Drug Delivery, Ann NY
Acad Sci. Vol. 618, 1991:610-612.
Hrushesky W. Temporally optimizable delivery systems: sine
qua non for the next therapeutic revolution. Journal of
Controlled Release 1991; 19:363-368.
Hrushesky W, Fader D, Berestka J, Sommer M, Hayes J, Cope F.
Diminishment of respiratory sinus arrhythmia foreshadows
doxorubicin-induced cardiomyopathy. Circulation 1991;
84:697-707.
Hrushesky W. What is the impact of the menstrual cycle on
outcome and recurrence in premenopausal women undergoing
breast cancer surgery? Oncology Bulletin 1991; 4:4 ,19.
Hrushesky W. Reprogramming SynchroMed pumps: unanticipated
inaccuracy. J Clin Oncol 1991; 9:1089-1094.
Hrushesky W. Cancer chronotherapy. Revue Europeenne de
Technologie Biomedicale 1991; 13:168-173.
Sánchez de la Peña S, Azar S, Hrushesky W. Murine
cardiovascular function during pregnancy: the fetus and
placenta as a closed-loop drug delivery system. In:
Hrushesky W, Langer R, Theeuwes F, eds. Temporal Control of
Drug Delivery, Ann NY Acad Sci. Vol. 618, 1991:619-622.
Roemeling R, Lanning R, Wagner H, DeConti R, Scheving L,
Hrushesky W. 5 Time specified delivery of chemotherapy by
implantable programmable pumps-preliminary data on
5-fluoro-2'-deoxyuridine. In: Rotman M, Rosenthal C, eds.
Concomitant Continuous Infusion Chemotherapy and Radiation.
Heidelberg: Springer Verlag, 1991:57-65.
Hrushesky W. Circadian timing and toxicity. In: Perry M, ed.
The Chemotherapy Source Book. Baltimore: Williams & Wilkins,
1990:165-212.
Grage T, Wesen C, Roemeling R, Lanning R, Olson G, Hrushesky
W. Reduction of hepatic toxicity by circadian modification
of intra-arterial hepatic infusion chemotherapy for
metastatic colorectal cancer to the liver. In: Lemmer B,
Hüller H, eds. Clinical Pharmacology. Vol. 6. München: W.
Zuckschwerdt Verlag, 1990:184-193.
Hrushesky W. Cancer chronotherapy and drug delivery systems,
Health is One's Own Responsibility-The Human Being, Medicine
and Society, Hannover, West Germany, 1990:241-263.
Gruber S, Canafax D, Cipolle R, Erdmann G, Burke B, Matas A,
Simmons R, Hrushesky W. Local immunosuppression of the
vascularized graft. Surgery 1990; 107:209-214.
Hrushesky W, Bluming A, Gruber S. Menstrual status and
breast cancer surgery-reply [Letter to editor]. Breast
Cancer Research and Treatment 1990; 16:121.
Hrushesky W. Health care for US veterans and others [Letter
to editor]. Lancet 1990:182.
Hrushesky W, Roemeling R, Lanning R, Rabatin J. Circadian
shaped infusions of FUDR for progressive metastatic renal
cell carcinoma. J Clin Oncol 1990; 8:1504-1513.
Hrushesky W. More evidence for circadian rhythm effects in
cancer chemotherapy: the fluoropyrimidine story. Cancer
Cells 1990; 2:65-68.
Hrushesky W. Cancer chemotherapy: a drug delivery challenge.
In: Hayes D, Pauly J, Reiter R, eds. Chronobiology: Its Role
in Clinical Medicine, General Biology and Agriculture, Part
A. New York: Wiley-Liss, Inc., 1990:1-10.
Hrushesky W, Bluming A, Gruber S. Menstrual influence on
surgical cure of breast cancer [Letter to editor]. Lancet
1990:984.
Gruber S, Cipolle R, Tzardis P, Skjei K, Jossart G, Abed J,
Canafax D, Burke B, Matas A, Hrushesky W. Pharmacodynamics
of local heparin infusion in a canine renal allograft model.
Journal of Pharmacology and Experimental Therapeutics 1990;
252:733-738.
Swoyer J, Rhame F, Hrushesky W, Sackett-Lundeen L, Sothern
R, Gale H, Haus E. Circadian rhythm alterations in HIV
infected subjects. In: Hayes D, Pauly J, Reiter R, eds.
Chronobiology: Its Role in Clinical Medicine, General
Biology and Agriculture, Part A. New York: Wiley-Liss, Inc.,
1990:437-450.
Sothern R, Rhame F, Suarez C, Fletcher C, Sackett-Lundeen L,
Haus E, Hrushesky W. Oral temperature rhythmometry and
substantial within-day variation in zidovudine levels
following steady-rate dosing in human immunodeficiency virus
(HIV) infection. In: Hayes D, Pauly J, Reiter R, eds.
Chronobiology: It's Role in Clinical Medicine, General
Biology and Agriculture, Part A. New York: Wiley-Liss, Inc.,
1990:67-76.
Teslow T, Zermeno A, Hrushesky W, Ashkenazi I. Chronobionet:
global and local area networking in the chronobiological
sciences. In: Hayes D, Pauly J, Reiter R, eds.
Chronobiology: Its Role in Clinical Medicine, General
Biology and Agriculture, Part B. New York: Wiley-Liss, Inc.,
1990:461-469.
Roemeling R, Hrushesky W. Determination of the therapeutic
index of floxuridine by its circadian infusion pattern. J
Natl Cancer Inst 1990; 82:386-393.
Roemeling R, Hrushesky W. Chronobiology of cancer therapy:
prototype use of fluoropyrimidine infusions. In: Lokich J,
ed. Cancer Chemotherapy by Infusion. Vol. 2nd edition.
Chicago: Precept Press, 1990:619-646.
Roemeling R, Hrushesky W. Fluoropyrimidine pharmacokinetics
are circadian stage dependent. In: Lemmer B, Hüller H, eds.
Clinical Pharmacology. Vol. 6. München: W. Zuckschwerdt
Verlag, 1990:169-183.
Roemeling R, DeMaria L, Salzer M, Connerty M, Wood P,
Portuese E, Sanchez de la Peña S, DeConti R, Chikkappa G,
Pasquale D, Ferro T, Hrushesky W. Circadian stage dependent
response to interleukin-2 in mouse spleen and bone marrow.
In: Reinberg A, Smolensky M, Labrecque G, eds. Annual Review
of Chronopharmacology. Vol. 6. Oxford: Pergamon Press,
1990:211-214.
Schraufek S, Sothern R, Voegele M, Ainsworth B, Serfass R,
Leon A, Khanuja H, Hrushesky W. Enhancement of respiratory
sinus arrhythmia by moderate exercise. In: Hayes D, Pauly J,
Reiter R, eds. Chronobiology: Its Role in Clinical Medicine,
General Biology and Agriculture, Part A. New York:
Wiley-Liss, Inc., 1990:283-296.
Wood P, Sanchez de la Pena S, Hrushesky W. Circadian timing
of recombinant human erythropoietin (rhEPO) in the mouse
affects hematopoietic response. In: Reinberg A, Smolensky M,
Labrecque G, eds. Annual Review of Chronopharmacology. Vol.
6. Oxford: Pergamon Press, 1990:173-176.
Kanabrocki E, Sothern R, Scheving L, Vesely D, Tsai T,
Shelstad J, Cournoyer C, Greco J, Mermall H, Nemchausky B,
Bushnell D, Kaplan E, Kahn S, Augustine G, Holmes E, Rumbyrt
J, Sturtevant R, Sturtevant F, Bremner F, Third J, McCormick
J, Mudd C, Dawson S, Olwin J, Sackett-Lundeen L, Haus E,
Halberg F, Pauly J, Hrushesky W. Circadian reference data
for men in fifth decade of life. In: Hayes D, Pauly J,
Reiter R, eds. Chronobiology: Its Role in Clinical Medicine,
General Biology and Agriculture, Part A. New York:
Wiley-Liss, Inc., 1990:771-782.
Vesely D, Kanabrocki E, Sothern R, Scheving L, Tsai T, Greco
J, Bushell D, Kaplan E, Rumbyrt J, Sturtevant R, Sturtevant
F, Bremner W, Third J, Hrushesky W, Olwin J. The circadian
rhythm of the N-terminus and C-terminus of the atrial
natriuretic factor prohormone. Chronobiol Intl 1990;
7:51-57.
Vesely D, Kanabrocki E, Sothern R, Scheving L, Tsai T, Greco
J, Bushnell D, Kaplan E, Rumbyrt J, Sturtevant R, Sturtevant
F, Bremner W, Third J, Hrushesky W, Olwin J. Circadian
variation of new cardiac hormones that lower blood pressure
and increase sodium excretion. In: Reinberg A, Smolensky M,
Labrecque G, eds. Annual Review of Chronopharmacology. Vol.
7. Oxford: Pergamon Press, 1990:137-140.
Lanning R, Roemeling R, Hrushesky W. Circadian-based
infusional FUDR therapy. Oncology Nursing Forum 1990;
17:49-56.
Lanning R, Hrushesky W. Outpatient time-specified infusion
of fluoropyrimidines by implanted pump is less costly than
flat delivery by external pump. In: Hayes D, Pauly J, Reiter
R, eds. Chronobiology: Its Role in Clinical Medicine,
General Biology and Agriculture, Part B. New York:
Wiley-Liss, Inc., 1990:397-409.
Roemeling R, Hrushesky W. Circadian patterning of continuous
floxuridine infusion reduces toxicity and allows higher dose
intensity in patients with widespread cancer. J Clin Oncol
1989; 7:1710-1719.
Hrushesky W, Gruber S, Sothern R, Hoffman R, Lakatua D,
Carlson A, Cerra F, Simmons R. Estral rhythms in natural
killer cell activity and metastatic behavior. In: Ades E,
Lopez C, eds. Natural Killer Cells and Host Defense. Basel:
Karger, 1989:258-261.
Roemeling R, Hrushesky W. Principles of chemotherapy and
immunotherapy for head and neck cancer. In: Paparella M,
Shumrick D, et al., eds. Otolaryngology. Vol. 1.
Philadelphia: W.B. Saunders, 1991:617-639.
Hrushesky W. Automatic chronotherapy: an integral part of
the future of medicine. In: Ensminger W, Selam J, eds.
Update in Drug Delivery Systems. Mount Kisco, NY: Futura
Publishing, 1989:13-33.
Sothern R, Halberg F, Hrushesky W. Circadian stage not time
of day characterizes doxorubicin susceptibility rhythm of
mice in continuous light. Annual Review of
Chronopharmacology 1989; 5:385-388.
Hrushesky W, Bluming A, Gruber S, Sothern R. Menstrual
influence on surgical cure of breast cancer. Lancet
1989:949-952.
Hrushesky W, Roemeling R, Sothern R. Circadian
chronotherapy: from animal experiments to human cancer
chemotherapy. In: Lemmer B, ed. Chronopharmacology: Cellular
and Biochemical Interactions. New York/Basel: Marcel Dekker,
1989:439-473.
Hrushesky W, Roemeling R, Sothern R. Preclinical and
clinical cancer chronotherapy. In: Ahrendt J, ed. Biological
Rhythms in Clinical Practice, 1989:225-251.
Sothern R, Levi F, Haus E, Halberg F, Hrushesky W. Control
of a murine plasmacytoma with doxorubicin-cisplatin depends
upon circadian stage of treatment. J Natl Cancer Inst 1989;
81:135-145.
Hrushesky W, Gruber S, Sothern R, Hoffman R, Lakatua D,
Carlson A, Cerra F, Simmons R. Splenocyte natural killer
cell activity is estrous-stage dependent and correlates
inversely with metastatic potential. In: Ades E, Lopez C,
eds. Natural Immunity and Cell Growth Regulators.
Switzerland: Karger, Basel, 1989.
Hrushesky W. Implantable drug delivery systems: the ultimate
home care, Proc World Congress on Home Care, Rome, Italy,
1989.
Gruber S, Venkataram S, Canafax D, Cipolle R, Bowers L,
Elsberry D, McGuiggan M, Hynes P, Ritz J, Gould F, Matas A,
Hrushesky W, Rahman Y-E. Liposomal formulation eliminates
acute toxicity and pump incompatability of parenteral
cyclosporine. Pharmaceutical Research 1989; 6:601-607.
Gruber S, Canafax D, Erdmann G, Cipolle R, Burke B, Rabatin
J, Hynes P, Gould F, Heil J, Ascher N, Simmons R, Najarian
J, Hrushesky W. The pharmacokinetic advantage of local
6-mercaptopurine infusion in a canine renal transplant
model. Transplantation 1989; 48:928-935.
Gruber S, Nichol K, Sothern R, Malone M, Potter J, Lakatua
D, Hrushesky W. Menstrual history and breast cancer surgery
[Letter to editor]. Breast Cancer Research and Treatment
1989; 13:278.
Gruber S, Burke B, Canafax D, Hrushesky W, Cipolle R,
Erdmann G, Matas A, Simmons R, Najarian J. Feasibility of
vascular catheter placement for intrarenal infusion in a
canine autotransplant model. Transplantation Proceedings
1989; 21:1125-1126.
Kanabrocki E, Snedeker P, Zieher S, Raymond R, Gordey J,
Bird T, Sothern R, Hrushesky W, Marks G, Olwin J, Kaplan E.
Circadian characteristics of dialyzable and non-dialyzable
human urinary electrolytes, trace elements and total solids.
Chronobiology Intl 1989:175-184.
Gruber S, Hrushesky W, Cipolle R, Erdmann G, Burke B, Skjei
K, Mueller R, Fryd D, Matas A, Sommons R, Canafax D. Local
immunosuppression with reduced systemic toxicity in a canine
renal allograft model. Transplantation 1989; 48:936-943.
Gruber S, Hrushesky W, Canafax D, Cipolle R, Burke B, Matas
A, Ascher N, Simmons R. Local prednisolone infusion of
canine renal allografts. Transplantation 1989; 48:1072-1075.
Tuchman M, Roemeling R, Hrushesky W, O'Dea R. Sources of
variability in dihydropyrimidine dehydrogenase activity in
human blood mononuclear cells. Enzyme 1989; 42:15-24.
Gruber S, Cipolle R, Canafax D, Rabatin J, Erdmann G, Hynes
P, Ritz J, Gould F, Hrushesky W. Circadian-shaped intrarenal
cyclosporine delivery. In: Reinberg A, Smolensky M,
Labrecque G, eds. Annual Review of Chronopharmacology.
Oxford: Pergamon Press, 1988:29-30.
Van Tornout J, Nesbit M, Bostrom B, Ramsay N, Somani S,
Langevin T, Lanning R, von Roemeling R, Hrushesky W.
Feasibility, safety and accuracy of an automated drug
delivery system suitable for chronochemotherapy in pediatric
patients. In: Reinberg A, Smolensky M, Labrecque G, eds.
Annual Review of Chronopharmacology. Vol. 5. Oxford:
Pergamon Press, 1988:431-432.
Hrushesky W. Automatic chronotherapy: an integral part of
the future of medicine. In: Hekkens W, Kerkhof G, Rietveld
W, eds. Advances in the Biosciences, Vol. 3, Trends in
Chronobiology. Vol. 3. Oxford: Pergamon Press, 1988:281-293.
Hrushesky W, Gruber S, Sothern R, Hoffman R, Lakatua D,
Carlson A, Cerra F, Simmons R. Natural killer cell activity:
age, estrous- and circadian-stage dependence and inverse
correlation with metastatic potential. J Natl Cancer Inst
1988; 80:1232-1237.
Hrushesky W, Berestka J, Roemeling R, Olshefski R, Langevin
T, Potish R, Delaney J, Ellefson M, Schwartz S. Methylene
blue protects intestinal mucosa from sublethal radiation
damage. Free Radical Biology and Medicine 1988; 5:207-213.
Hrushesky W. Rationnel de l'administration des medicaments a
l'aide d'un systme de perfusion automatise, pilote par
ordinateur (chronotherapie). Cancer Communication 1988;
2:169-179.
Hrushesky W, Damascelli B, Ravasi G, Spreafico C, Lutman R,
Valvassori L, Bellegotti L, Marchianó A, Del Nero A,
Bonalumi M. Cronoterapia infusionale mediante sistemi
automatici a totale impianto sottocutaneo programmabili per
telemetria. Medico e Paziente, XIV 1988; 10:56-65.
Gruber S, Cipolle R, Canafax D, Erdmann G, Burke B, Rabatin
J, Hynes P, Ritz J, Gould F, Ascher N, Simmons R, Hrushesky
W. An implantable pump for intrarenal infusion of
immunosuppressants in a canine autotransplant model.
Pharmaceutical Research 1988; 12:781-785.
Cipolle T, Canafax D, Rabatin J, Bowers L, Sutherland D,
Hrushesky W. Two-dose chronopharmacokinetic optimization of
cyclosporine in pancreas transplant patients. In: Reinberg
A, Smolensky M, Labrecque G, eds. Annual Review of
Chronopharmacology 5. Oxford: Pergamon Press, 1988:13-16.
Gruber S, Hoffman R, Sothern R, Lakatua D, Carlson A,
Simmons R, Hrushesky W. Splenocyte natural killer cell
activity and metastatic potential are inversely dependent on
estrous stage. Surgery 1988; 104:398-403.
Hrushesky W, Roemeling R, Fraley E, Rabatin J.
Circadian-based infusional chrono-chemotherapy controls
progressive metastatic renal cell carcinoma. Seminars in
Surgical Oncology 1988; 4:110-115.
Cipolle R, Canafax D, Rabatin J, Bowers L, Sutherland D,
Hrushesky W. Time-dependent disposition of cyclosporine
after pancreas transplantation, and application of
chronopharmacokinetics to improve immunosuppression.
Pharmacotherapy 1988; 8:47-51.
Hrushesky W. The rationale for non-zero-order drug delivery
using automatic, computer-based drug delivery systems
(chronotherapy). J Biol Response Modifiers 1988; 6:587-598.
Kanabrocki E, Sothern R, Scheving L, Halberg F, Pauly J,
Greco J, Nemchausky B, DeBartolo M, Kaplan E, McCormick J,
Olwin J, Marks G, Bird T, Redmond D, Graeber R, Ferrara A,
Hrushesky W. Ten-year replicated circadian profiles for 36
physiological, serological and urinary variables in healthy
man. Chronobiology International 1988; 5:237-284.
Ratajczak H, Thomas P, Vollmuth T, Heck D, Sothern R,
Hrushesky W. Seasonal variations of host resistance and in
vitro antibody formation of spleen cells from the B6C3F1
mouse. In: Reinberg A, Smolensky M, Labrecque G, eds. Annual
Review of Chronopharmacology 5. Oxford: Pergamon Press,
1988:49-52.
Ratajczak H, Sothern R, Hrushesky W. Estrous influence on
surgical cure of a mouse breast cancer. Journal of
Experimental Medicine 1988; 168:73-83.
Roemeling R, Rabatin J, Fraley E, Hrushesky W. Progressive
metastatic renal cell carcinoma controlled by continuous
FUDR infusion. J Urol 1988; 139:259-262.
Roemeling R, Rabatin J, Tuchman M, Hrushesky W. Circadian
timing and mode of fluoropyrimidine administration markedly
impact organ-specific toxicity and maximal dose intensity.
In: Reinberg A, Smolensky M, Labrecque G, eds. Annual Review
of Chronopharmacology 5. Oxford: Pergamon Press,
1988:427-430.
Canafax R, Cipolle R, Hrushesky W, Rabatin J, Min D, Graves
N, Sutherland D, Bowers L. Increased evening exposure to
cyclosporine and metabolites. In: Reinberg A, Smolensky M,
Labrecque G, eds. Annual Review of Chronopharmacology.
Oxford: Pergamon Press, 1988:5-8.
Mormont M, Roemeling R, Sothern R, Berestka J, Langevin T,
Hrushesky W. Circadian rhythm and seasonal dependence in
tolerance of mice to 4'-epi-doxorubicin. Investigational New
Drugs 1988; 6:273-283.
Canafax D, Cipolle R, Hrushesky W, Rabatin J, Sutherland D,
Bowers L. The chronopharmacokinetics of cyclosporine and its
metabolites in recipients of pancreas allografts. Transplant
Proc 1988; 20:471-477.
Tuchman M, Roemeling R, Lanning R, Sothern R, Hrushesky W.
Sources of variability of dihydropyrimidine dehydrogenase
activity in human blood mononuclear cells. In: Reinberg A,
Smolensky M, Labrecque G, eds. Annual Review of
Chronopharmacology 5. Oxford: Pergamon Press, 1988:399-402.
Sothern R, Haus R, Langevin T, Popovich J, Wick M, von
Roemeling R, Hrushesky W. Profound circadian stage
dependence of mitomycin-c toxicity. In: Reinberg A,
Smolensky M, Labrecque G, eds. Annual Review of
Chronopharmacology. Oxford: Pergamon Press, 1988:389-392.
Touitou Y, Sothern R, Levi F, Focan C, Bogdan A, Auzéby A,
Franchimont P, von Roemeling R, Hrushesky W. Sources of
predictable tumor marker variation within the so-called
normal range: circadian and circannual aspects of plasma
carcinoembryonic antigen (CEA) in health and cancer. Journal
of Tumor Marker Oncology 1988; 3:351-359.
Scheving L, Tsai T, Sothern R, Hrushesky W. Circadian
susceptibility-resistance cycles to radiation and their
manipulability by methylene blue (a non-toxic, in vivo
oxidation-reduction complex). Pharmacology and Therapeutics
1988; 39:397-402.
Hrushesky W, Nygaard S, Young J. Timing may be a critical
factor in drug therapy. Cancer Treat Rep 1987; 71:1321.
Hrushesky W. A case for clinical concentration upon the
ultradian frequency domain. In: Scheving L, Halberg F, Ehret
C, eds. Chronobiotechnology and Chronobiological
Engineering. The Netherlands: Martinus Nijhoff,
1987:327-330.
Hrushesky W, Roemeling R, Wood P, Langevin T, Lange P,
Fraley E. High dose intensity, circadian timed,
doxorubicin-cisplatin adjuvant therapy for bladder cancer.
Cancer Treat Rep 1987; 71:915-919.
Hrushesky W, Roemeling R, Wood P, Langevin, TR, Lange P,
Fraley E. High-dose intensity systemic therapy of metastatic
bladder cancer. J Clin Oncol 1987; 5:450-455.
Focan C, Collette J, Franchimont P, Levi F, Touitou Y,
Hrushesky W. Rythmes biologiques et marqueurs tumoraux chez
l'homme. Acta Gastroenterologica Belgica 1987; XL:12-21.
Roemeling R, Hrushesky W. Circadian pattern of continuous
FUDR infusion reduces toxicities. In: Pauly J, Scheving L,
eds. Advances in Chronobiology. New York: Alan Liss,
1987:357-373.
Roemeling R, Hrushesky W, Fraley E. Long-term control of
locally advanced transitional cell bladder cancer (TCCB) by
high-dose intensity, circadian-based adjuvant chemotherapy.
In: Salmon S, ed. Adjuvant Therapy of Cancer V. Orlando:
Grune and Stratton, 1987:571-580.
Hrushesky W, Roemeling R. The importance of proper circadian
timing of cancer chemotherapy. In: Droz J, Cvitkovic E,
Armand J, Khoury S, eds. Clinical Cancer Chemotherapy
Handbook. Paris: Fondation Internationale p'our
l'Information Scientifique, 1987:27-30.
Hrushesky W, Roemeling R, Rabatin J. Programmable automatic
drug delivery: new perspectives for cancer therapy. In:
Ensminger W, ed. Infusion Systems in Medicine. New York:
Futura Publishing, 1987:175-188.
Ratajczak H, Sothern R, Hrushesky W. Single cosinor analysis
of vaginal smear cell types quantifies mouse estrous cycle
and its alteration by mammary adenocarcinoma. In: Reinberg
A, Smolensky M, Labrecque G, eds. Annual Review of
Chronopharmacology. Vol. 3. New York: Pergamon Press,
1986:223-226.
Skubitz K, Wick M, Skubitz A, Langevin T, Olshefski R, von
Roemeling R, Sothern R, Hrushesky W. Timing of amphotericin
B therapy is a critical determinant of toxicity. In:
Reinberg A, Smolensky M, Labrecque G, eds. Annual Review of
Chronopharmacology. Vol. 3. New York: Pergamon Press,
1986:183-186.
Mormont C, Berestka J, Mushiya T, Langevin T, von Roemeling
R, Rabatin J, Sothern R, Hrushesky W. Circadian dependency
of vinblastin toxicity. In: Reinberg A, Smolensky M,
Labrecque G, eds. Annual Review of Chronopharmacology. New
York: Pergamon Press, 1986:187-189.
Focan C, Focan-Henrard D, Frere M, Hung S, Castronovo V,
Collette J, Franchimont P, Touitou Y, Levi F, Roemeling R,
Hrushesky W. Circadian CEA variability: when to sample
[Letter to editor]. J Clin Oncol 1986; 4:607.
Roemeling R, Hrushesky W. Advanced transitional cell bladder
cancer: a treatable disease. Seminars in Surgical Oncology
1986; 2:76-89.
Roemeling R, MacDonald M, Langevin T, Buchwald H, Hrushesky
W. Chemotherapy via implanted infusion pump: new
perspectives for delivery of long-term continuous treatment.
Oncol Nursing Forum 1986; 13:17-24.
Focan C, Collette J, Levi F, Hrushesky W, Touitou Y,
Franchimont P. Circadian rhythms in human carcinoembryonic
antigen (CEA), alphafetoprotein (AFP) and prostatic acid
phosphatase (PAP): evidence of chronopathology in cancer.
In: Reinberg A, Smolensky M, Labrecque G, eds. Annual Review
of Chronopharmacology. Vol. 3. New York: Pergamon Press,
1986:417-420.
Focan C, Focan-Henrard D, Collette J, Mechkouri M, Lévi F,
Hrushesky W, Touitou Y, Franchimont P. Cancer-associated
alteration of circadian rhythms in carcinoembryonic antigen
(CEA) and alpha-fetoprotein (AFP) in humans. Anticancer
Research 1986; 6:1137-1144.
Roemeling R, Olshefski R, Langevin T, Berestka J, Reusch J,
Reusch JE, Lakatua D, Wick M, Hrushesky W. Cisplatin
chronotherapy and disulfiram rescue reduce toxicity without
interfering with anticancer activity: animal findings and
preliminary clinical experiences. Chronobiol Int 1986;
3:55-64.
Hrushesky W, Langevin T, Fader D, Herzog C. The respiratory
sinus arrhythmia: an ultradian rhythm pregnant with
medically relevant information. In: Reinberg A, Smolensky M,
Labrecque G, eds. Annual Review of Chronopharmacology. Vol.
3. New York: Pergamon Press, 1986:353-356.
Hrushesky W. Circadian drug schedule affects drug toxicity,
ovarian cancer response, and patient survival. In: Reinberg
A, Smolensky M, Labrecque G, eds. Annual Review of
Chronopharmacology. Vol. 3. New York: Pergamon Press,
1986:203-206.
Hrushesky W, Roemeling R. Chemotherapy-induced vomiting:
circadian drug timing as a source of predictable
within-patient variability. Cancer Treat Rep 1986;
70:1347-1348.
Roemeling R, Wick M, Rabatin J, Berestka J, Langevin T,
Lakatua D, Mormont C, Mushiya T, Hrushesky W. Circadian
stage dependence of FUDR toxicity. In: Reinberg A, Smolensky
M, Labrecque G, eds. Annual Review of Chronopharmacology.
Vol. 3. New York: Pergamon Press, 1986:191-194.
Roemeling R, Langevin T, Rabatin J, Buchwald H, Kennedy B,
Hrushesky W. Automatic chronotherapy using an implanted
programmable pump (Medtronic, Inc.). In: Reinberg A,
Smolensky M, Labrecque G, eds. Annual Review of
Chronopharmacology. Vol. 3. New York: Pergamon Press,
1986:241-244.
Roemeling R, Hrushesky W, Kennedy B, Buchwald H. Programmed
automatic FUDR chronotherapy improves therapeutic index,
Proc 42nd Ann Sessions of the Forum on Fundamental Surgical
Problems, 72nd Ann Clin Cong, New Orleans, 1986:400-402.
Bowers L, Rabatin J, Wick M, Canafax D, Hrushesky W, Benson
E. Circadian pharmacodynamics of cyclosporine in rats and
man. In: Reinberg A, Smolensky M, Labrecque G, eds. Annual
Review of Chronopharmacology. Vol. 3. New York: Pergamon
Press, 1986:219-222.
Hrushesky W, Roemeling R. Reply to: Rausto Roila et al.:
Antiemetic effect of high-dose metoclopramide [Letter to
editor]. J Clin Oncol 1986; 4:441.
Focan C, Castronovo V, Collette J, Focan-Henrard D, Frére M,
Le Hung S, Touitou Y, Lévi F, Hrushesky W, Franchimont P.
Alteration of circadian variation in serum concentrations of
carcinoembryonic antigen (CEA) in cancer. In: Peeters H, ed.
Protides of the Biological Fluids: Proceedings of the
Thirty-Second Colloquium. Oxford/New York/Toronto: Pergamon
Press, 1985:703-705.
Magnus G, Cavallini M, Halberg F, Cornelissen G, Sutherland
D, Najarian J, Hrushesky W. Circadian toxicity of
cyclosporine. Toxicol Appl Pharmacol 1985; 77:181.
Roemeling R, Christiansen N, Hrushesky W. Lack of antiemetic
effect of high-dose metoclopramide. J Clin Oncol 1985;
3:1273-1276.
Trugman J, Hogencamp H, Roelofs R, Hrushesky W. Cisplatin
neurotoxicity: failure to demonstrate vitamin B12
inactivation. Cancer Treat Rep 1985; 69:453-455.
Rosenberg C, Hrushesky W, Langevin T, Kennedy B. Hormonal
and chemotherapeutic treatment of prostatic carcinoma;
Dunning adenocarcinoma of the prostate in Copenhagen-Fischer
rats. Oncol 1985; 42:48-54.
Hrushesky W. Cyclosporine timing and kidney damage. New Eng
J Med 1985:184.
Hrushesky W. The effect of anticancer drug timing upon
therapeutic index. In: Reitveld W, ed. Clinical Aspects of
Chronobiology: Meducation Service Hoechst, 1985:141-157.
Hrushesky W. Distinguishing between renal allograft and
cyclosporine nephrotoxicity. Lancet 1985; 8453:501.
Hrushesky W. Circadian timing of cancer chemotherapy.
Science 1985; 228:73-75.
Hrushesky W, Haus E, Lakatua D, Langevin T, Halberg F,
Kennedy B. Marker rhythms for cancer chrono-chemotherapy.
In: Haus E, Cabet H, eds. Chronobiology. New York: Karger
Publishers, 1985:493-499.
Hrushesky W, Olshefski R, Wood P, Eaton J, Meshnik S.
Modifying intracellular redox balance: an approach to
improving therapeutic index. Lancet 1985; 8428:565-567.
Hrushesky W, Olshefski R, Wood P, Meshnick S, Babson J,
Woods W, Eaton J. Methylene blue ameliorates doxorubicin
toxicity. In: Superoxide and Superoxide Dismutase in
Chemistry, Biology and Medicine, Superoxide and Superoxide
Dismutase, Rome, Italy, 1985. Elsevier:642-646.
Hrushesky W. Medical relevance of rhythmic biological time
structure, 5th Intl Mtg on Clin Lab Organization and
Management, Haifa, Israel, 1985. Karger Publishers:92-100.
Hrushesky W. Utility of non-invasive instantaneous screening
test for drug-induced cardiac damage [Letter to editor]. J
Clin Oncol 1985; 3:1438.
Hrushesky W. Biological time structure and some of its
implications in cancer medicine. table ronde roussel uclaf
1985; 54:30-35.
Kennedy B, Covell D, Hrushesky W. Implantable and
extracorporeal programmable drug delivery systems: what to
program. In: Reinberg A, Smolensky M, Labrecque G, eds.
Annual Review of Chronopharmacology. Vol. 1. New York:
Pergamon Press, 1984:193-196.
Touitou Y, Hrushesky W, Levi F, Focan C, Auzeby A, Bogdan A.
Plasma carcinoembryonic antigen rhythm in patients with
ovarian cancer: effects of chemotherapy. In: Reinberg A,
Smolensky M, Labrecque G, eds. New York: Pergamon Press,
1984:141-143.
Chute E, Rhode T, Rupp W, Goldenberg E, Hrushesky W,
Buchwald H. Diurnal variation in glucose levels can impede
single rate continuous intravenous insulin therapy. In:
Reinberg A, Smolensky M, Labrecque G, eds. Annual Review of
Chronopharmacology. Vol. 1. New York: Pergamon Press,
1984:185-188.
Hrushesky W, Shimp W, Kennedy B. Lack of age-dependent
cisplatin nephrotoxicity. Am J Med 1984; 76:579-584.
Hrushesky W, Fader D, Gilbertsen V, Schmitt O. The
respiratory sinus arrhythmia as an objective measure of
cardiac age. Science 1984; 224:1001-1004.
Hrushesky W. Chemotherapy timing: An important variable in
toxicity and response. In: Perry M, Yarbro J, eds. Toxicity
of Chemotherapy. New York: Grune and Stratton, 1984:449-477.
Hrushesky W. The effect of anticancer drug timing upon
therapeutic index. In: Wiernik P, ed. Mediguide to Oncology.
Vol. 4, 1984:1-5.
Hrushesky W. Selected aspects of cisplatin nephrotoxicity in
the rat and man. In: Hacker M, Douple E, Krakoff I, eds.
Platinum Coordination Complexes in Cancer Chemotherapy:
Martinus Nijhoff Publishers, 1984:165-186.
Roelofs R, Hrushesky W, Rogin J, Rosenberg L. Peripheral
sensory neuropathy and cisplatin chemotherapy. Neurol 1984;
34:934-938.
Hrushesky W. The sine-o-graph pulse monitor: a potential
quantifier of cardiovascular wellness. In: Reinberg A,
Smolensky M, Labrecque G, eds. Annual Review of
Chronopharmacology. Vol. 1. New York: Pergamon Press,
1984:325-328.
Hrushesky W, Vukelich M. Circadian mesor of recumbent
pulse-cost effective predictor of doxorubicin-induced
congestive heart failure. Chronobiol Intl 1984; 1:59-66.
Hrushesky W, Vukelich M, Steiner B, Dell I, Mukai K. 24-hour
mean pulse: a simple predictor for doxorubicin-induced
cardiac damage. Am J Med 1984; 77:399-406.
Hrushesky W. Circadian chronopharmacokinetics and
chronotoxicology of doxorubicin and cisplatin in human
beings with cancer. In: Reinberg A, Smolensky M, Labrecque
G, eds. Annual Review of Chronopharmacology. Vol. 1. New
York: Pergamon Press, 1984:119-122.
Hrushesky W, Merdink J, Abdel-Monem M. Circadian rhythmicity
of polyamine excretion. Cancer Res 1983; 43:3944-3947.
Hrushesky W. The clinical application of chronobiology to
oncology. Am J Anat 1983; 168:519-542.
Hrushesky W. Adjuvant chemotherapy for transitional cell
carcinoma of the urinary bladder [Editorial]. World Urology
Update 1983; 1:6.
Bixby E, Levi F, Haus R, Sackett L, Haus E, Halberg F,
Hrushesky W. Circaseptan aspects of murine nephrotoxicity of
cisdiamminedichloroplatinum. In: Takahashi R, Halberg F,
Walker C, eds. Toward Chronopharmacology. New York: Pergamon
Press, 1982:339-347.
Levi F, Hrushesky W, Blomquist C, Lakatua D, Haus E, Halberg
F, Kennedy BJ. Reduction of cis-diamminedichloroplatinum
nephrotoxicity in rats by optimal circadian timing. Cancer
Res 1982; 42:950-955.
Levi F, Hrushesky W, Halberg F, Haus E, Langevin T, Kennedy
B. Lethal nephrotoxicity and hematologic toxicity of
cis-diamminedichloroplatinum ameliorated by optimal
circadian timing. Eur J Cancer Clin Oncol 1982; 18:471-477.
Hrushesky W, Borch R, Levi F. Circadian time dependence of
cisplatin urinary pharmacokinetics. Clin Pharm Ther 1982;
32:330-339.
Hrushesky W. Bone marrow suppression from doxorubicin and
cis-diamminedichloroplatinum is substantially dependent upon
both circadian and circannual state of administration [Cell
Proliferation, Cancer and Cancer Therapy. A Conference in
Honor of Anna Goldfelder, R Baserga (ed)]. Ann NY Acad Sci
1982; 397:293-295.
Hrushesky W, Levi F, Halberg F, Kennedy B. Circadian stage
dependence of cis-diamminedichloroplatinum lethal toxicity
in rats. Cancer Res 1982; 42:945-949.
Levi F, Hrushesky W, Borch R, Pleasants M, Kennedy B,
Halberg F. Cisplatin urinary pharmacokinetics and
nephrotoxicity: A common circadian mechanism. Cancer Treat
Rep 1982; 66:1933-1938.
Magnus G, Cavallini M, Halberg F, Cornelissen G, Sutherland
D, Hrushesky W. Cyclosporine tolerance improved by circadian
timing. S.I.R.M.C.E., Influence of Environment of Man,
1982:13-23.
Levi F, Hrushesky W, Kennedy B. Perspecitves en
chronochimiotherapie anticancereuse. Le Quotidien Du Medicin
Chronobiologia 1981; Suppl 2546:46-51.
Hrushesky W, Levi F, Halberg F, Haus E, Scheving L, Sanchez
de la Peña S, Medini E, Brown H, Kennedy BJ. Clinical
chrono-oncology. In: Scheving L, Halberg F, eds.
Chronobiology: Principles and Applications to Shifts in
Schedules, 1980:513-533.
Hrushesky W. Unusual pigmentary changes associated with
5-fluorouracil therapy. Cutis 1980; 26:181-182.
Haus E, Halberg F, Sothern R, Lakatua D, Scheving L, Sanchez
de la Peña S, Sanchez E, Melby J, Wilson T, Brown H, Berg H,
Lévi F, Culley D, Halberg E, Hrushesky W, Pauly J.
Time-varying effects in mice and rats of several synthetic
ACTH preparations. Chronobiologia 1980; 7:211-226.
Levi F, Hrushesky W, Haus E, Halberg F, Scheving L, Kennedy
B. Experimental chrono-oncology. In: Scheving L, Halberg F,
eds. Chronobiology: Principles and Applications to Shifts in
Schedules, 1980:481-511.
Levi F, Halberg F, Haus E, Sanchez de la Peña S, Sothern R,
Halberg E, Hrushesky W, Brown H, Scheving L, Kennedy BJ.
Synthetic adrenocorticotropin for optimizing murine
circadian chronotolerance for adriamycin. Chronobiologia
1980; 7:227-244.
Sothern R, Hrushesky W, Halberg F, Haus E, Kennedy B.
Circadian temperature rhythm in LOU rats with and without
immunocytoma during polychronochemotherapy with adriamycin
and cis-diamminedichloroplatinum II. In: Reinberg A, Halberg
F, eds. Chronopharmacology. Oxford/New York: Pergamon Press,
1979:391.
Halberg E, Halberg F, Vener K, Scheving L, Cornelissen G, De
Prins J, Hrushesky W, Kennedy BJ. Twenty-four hour
synchronized chronotolerance of cis-diamminedichloroplatinum
(II) by rats on 8h and 12h photofraction gauged by acrophase
and paraphase of rectal temperature. In: Reinberg A, Halberg
F, eds. Chronopharmacology. Oxford/New York: Pergamon Press,
1979:377-387.
Gordon L, Hrushesky W, Oken M, Kay N, Rydell R. Chronic
lymphocytic leukemia in association with a second
lymphoproliferative disorder: response to chemotherapy in
two cases. Med Ped Oncol 1979; 7:111-117.
Hrushesky W. Subcutaneous heparin-induced thrombocytopenia.
Arch Int Med 1978; 138:1489-1491.
Hrushesky W. Platelets: Too sticky or too many. Ann Int Med
1978; 88:845.
Hrushesky W. Thrombocytopenia induced by low-dose
subcutaneous heparin. Lancet 1977; 2:1286.
Hrushesky W, Murphy G. Current status of the therapy of
advanced renal carcinoma. J Surg Oncol 1977; 9:277-288.
Hrushesky W. Serpentine supravenous 5-fluorouracil
hyperpigmentation. Cancer Treat Rep 1976; 60:639.
Hrushesky W, Slavik M, Penta J, Muggia F. The "other"
asparaginase. Med Ped Oncol 1976; 2:441-442.
Hrushesky W. L-asparaginase activity in acute
non-lymphocytic leukemia. Cancer Treat Rep 1976; 60:966.
Williams P, Hrushesky W, Gaeta J, Murphy G. The influence of
hormone therapy on rats treated with the carcinogen
ethylmethanesulfonate. Res Comm Chem Path Pharmacol 1974;
7:25-30.
Hrushesky W, Murphy G. Evaluation of chemotherapeutic agents
in a new murine renam carcinoma model. J Natl Cancer Inst
1974; 52:1117-1122.
Hrushesky W, Murphy G. Investigation of new renal tumor
model. J Surg Res 1973; 15:327-336.
Murphy G, Hrushesky W. A murine renal cell carcinoma. J Natl
Cancer Inst 1973; 50:1013-1025.
Hrushesky W, Sampson D, Murphy G. Carcinogenicity of
ethylmethanesulfonate. J Natl Cancer Instit 1972;
49:1077-1083.
Hrushesky W, Sampson D, Murphy G. Lymphocyturia in renal
allograft rejection. Arch Surg 1972; 105:424-426.
For recent
abstracts, click here
|
